Received: 3 June 2022
Accepted: 8 November 2022
First Online: 16 November 2022
: According to national regulations no ethical vote was needed because this is an anonymous case description. The patient signed a consent for publication. We adhered to the declaration of Helsinki and the Austrian Data Safety Authority instructions by anonymising all personal data.
: The patient signed a consent for publication. A copy of the written consent is available for review by the Editor of this journal.
: Klaus Berek has participated in meetings sponsored by, received travel funding from or received honoraria for acting as an advisor/speaker for Roche, Biogen, TEVA and Sanofi.Astrid Grams reports no conflicts of interest.Christian Uprimny reports no conflicts of interest.Manuela Prieschl reports no conflicts of interest.Melanie Ramberger reports no conflicts of interest.Iris Unterberger reports no conflicts of interest.Florian Deisenhammer has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Almirall, Alexion, Biogen, Celgene, Genzyme-Sanofi, Merck, Novartis Pharma, Roche, and TEVA ratiopharm. His institution has received research grants from Biogen and Genzyme Sanofi. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders) and review editor of Frontiers Neurology.Markus Reindl is supported by research grants from the Austrian Science Fund (FWF project P32699), the Austrian Research Promotion Agency, Euroimmun and Roche; consulting fees and advisory board from Roche (to institution). He works at the Clinical Department of Medical University of Innsbruck which offers diagnostic testing for MOG and other autoantibodies.Harald Hegen has participated in meetings sponsored by, received speaker honoraria or travel funding from Biogen, Celgene, Merck, Novartis, Sanofi-Genzyme, Siemens, Teva, and received honoraria for acting as consultant for Biogen, Celgene, Novartis and Teva.